抗 PD-1 纳米抗体装甲 MSLN CAR-T 治疗恶性间皮瘤:临床前与临床研究
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.
这些发现表明,NAC-T 细胞疗法对恶性间皮瘤患者而言是一种有前景的治疗策略。
FRONTIER PAPERS
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.
这些发现表明,NAC-T 细胞疗法对恶性间皮瘤患者而言是一种有前景的治疗策略。
Immunotherapy resistance and strategies in malignant pleural mesothelioma.
恶性胸膜间皮瘤(MPM)仍然是最具侵袭性的胸部恶性肿瘤之一,其特征是对手术、化疗和放疗等常规治疗手段具有深度耐药性,导致生存结局持续不佳。
Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and firs
我们的研究突出了靶向 MSLN 的多链 DAP-CAR-T 细胞疗法治疗卵巢癌和间皮瘤患者的安全性和疗效。
Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future.
Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells.
间皮素(MSLN)在超过90%的恶性胸膜间皮瘤和胰腺腺癌中过表达,而在正常组织中表达极低,因此是一个理想的免疫治疗靶点。
Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice.
MSLN靶向CAR T细胞疗法的区域递送在原位CRLM NSG小鼠模型和PDX模型中具有令人鼓舞的结果,并将肿瘤微环境从冷肿瘤转化为热肿瘤。本研究可能为CRLM提供一种新的治疗途径。需要进一步的临床研究。
共 6 条
MEMBER ACCOUNT
登录成功会直接打开下一页。